首页> 外国专利> STANDARD DOSES FOR IMMEDIATE RELEASE OF GHB OR ONE OF ITS THERAPEUTICALLY ACCEPTABLE SALTS, ADAPTABLE BY THE ORAL ROLL, AND THEIR APPLICATION TO MAINTAIN ALCOHOL REFUSAL

STANDARD DOSES FOR IMMEDIATE RELEASE OF GHB OR ONE OF ITS THERAPEUTICALLY ACCEPTABLE SALTS, ADAPTABLE BY THE ORAL ROLL, AND THEIR APPLICATION TO MAINTAIN ALCOHOL REFUSAL

机译:立即释放GHB或其可治疗的一种盐的标准剂量,可通过口腔用药调整,并用于维持酒精中毒

摘要

The present invention relates to immediate release, standard doses of GHB or one of its therapeutically acceptable salts, administered by oral route. Such standard doses contain from 0.37 to 1.75 g of GHB, more often in the form of sodium oxybate; when doses in the form of granules, such granules have the following composition (wt.% relative to the total mass of the granules): active ingredient (sodium oxybate): 50-60%; effervescent agent: 5-15%; thinner: 2-18%; binder: 3-10%; substrate (solid core granules): 15-25%; coating agent / flavoring / sweetening agent / lubricant: 3-6%. They are used to support the rejection of alcohol in patients with low or moderate alcohol dependence or with severe or very severe alcohol dependence, suffering from or not suffering from liver disease.
机译:本发明涉及通过口服途径施用的速释,标准剂量的GHB或其治疗上可接受的盐之一。此类标准剂量含有0.37至1.75 g的GHB,通常为羟丁酸钠的形式;当以颗粒剂的形式给药时,这些颗粒具有以下组成(相对于颗粒总质量的重量%):活性成分(次生酸钠):50-60%;泡腾剂:5-15%;稀释剂:2-18%;粘合剂:3-10%;底物(固体核心颗粒):15-25%;涂层剂/调味剂/甜味剂/润滑剂:3-6%。它们用于在患有或未患有肝病的低或中度酒精依赖或严重或非常严重酒精依赖的患者中支持酒精排斥。

著录项

  • 公开/公告号EA201892223A1

    专利类型

  • 公开/公告日2019-03-29

    原文格式PDF

  • 申请/专利权人 ДЕБРЕЖА Э АССОСЬЕ ФАРМА;

    申请/专利号EA20180092223

  • 发明设计人 ЖЮЛЬЕН;

    申请日2017-03-30

  • 分类号A61K31/19;A61K9/50;

  • 国家 EA

  • 入库时间 2022-08-21 12:02:33

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号